Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, has announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, offering investors a direct opportunity to engage with the company's leadership.
The company intends to highlight several recent advancements, including the progression of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This milestone reflects Oncotelic's commitment to advancing its oncology pipeline. Additionally, the expansion of European clinical sites underscores the company's global reach and its efforts to accelerate patient enrollment and data collection.
Oncotelic will also showcase the validation of its proprietary Deciparticle platform through peer-reviewed publications. The Deciparticle technology is designed to improve drug delivery and efficacy, potentially enhancing treatment outcomes for cancer patients. The company's scalable cGMP manufacturing capabilities are another focal point, ensuring that its therapies can be produced at commercial scale when approved.
Furthermore, the presentation will cover Oncotelic's continued development of AI-driven drug discovery, robotics, and nanomedicine platforms. These innovative approaches aim to streamline the drug development process and reduce costs, positioning the company at the forefront of precision medicine.
The significance of this announcement lies in the company's ability to communicate its progress to the investment community. For a clinical-stage biotech, transparency and milestones are crucial for building investor confidence. The live Q&A session provides an opportunity for stakeholders to clarify doubts and gain deeper insights into the company's strategic direction.
According to the press release, the full details are available at https://nnw.fm/fGHUt. The company also directs interested parties to its newsroom for the latest updates at https://nnw.fm/OTLC.
Oncotelic Therapeutics focuses on developing innovative therapies for cancer and other serious diseases, leveraging precision medicine, RNA therapeutics, artificial intelligence, and advanced nanomedicine delivery technologies. Its portfolio includes clinical-stage oncology assets and the proprietary Deciparticle drug delivery technology.
The company's AI-enabled drug discovery platforms and scalable GMP manufacturing capabilities are designed to accelerate development while improving patient outcomes. As Oncotelic continues to advance its pipeline, the investor conference presentation serves as a platform to highlight its potential to disrupt the oncology space.
